Figures & data
Figure 1 MARINA trial design.
Figure 2 MARINA trial: after 2 years mean visual acuity had increased by 6.6 lines in the ranibizumab 0.5 mg group versus a decrease of 14.9 lines in the sham group. This favorable outcome was independent of membrane type (minimally classic or purely occult CNV), the initial visual acuity, or the lesion size. Adapted with permission from CitationRosenfeld PJ, Brown DM, Heier JS, et al. 2006a. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med, 355:1419–31. Copyright © 2006. Massachusetts Medical Society. All rights reserved.
Figure 3 ANCHOR trial design.
Figure 4 In patients with classic subfoveal CNV due to AMD, ranibizumab prevented visual loss in a significantly higher number of patients than PDT (12-month results modified according to CitationBrown et al 2006; 24-month results according to CitationSchmidt-Erfurth et al 2007).
Figure 5 In patients with classic subfoveal CNV due to AMD, ranibizumab improved vision significantly in up to 41% of patients (12-month results modified according to CitationBrown et al 2006; 24-month results according to CitationSchmidt-Erfurth et al 2007).
